Pharvaris (NASDAQ:PHVS) Shares Gap Down – Here’s Why

Posted by Joseph Casey on Mar 13th, 2025

Pharvaris (NASDAQ:PHVS – Get Free Report) shares gapped down before the market opened on Tuesday . The stock had previously closed at $14.90, but opened at $14.52. Pharvaris shares last traded at $15.03, with a volume of 5,780 shares.

Wall Street Analysts Forecast Growth

Separately, JMP Securities lifted their target price on shares of Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, January 31st.

Check Out Our Latest Stock Analysis on Pharvaris

Pharvaris Trading Up 2.2 %

The firm has a 50 day moving average of $17.20 and a two-hundred day moving average of $19.15. The stock has a market capitalization of $855.20 million, a PE ratio of -5.84 and a beta of -3.02.

Institutional Investors Weigh In On Pharvaris

Several institutional investors and hedge funds have recently made changes to their positions in the business. Public Employees Retirement System of Ohio purchased a new stake in shares of Pharvaris in the third quarter valued at about $57,000. JPMorgan Chase & Co. increased its position in Pharvaris by 1,125.3% during the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock worth $59,000 after buying an additional 2,847 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Pharvaris in the fourth quarter valued at $64,000. Barclays PLC acquired a new stake in shares of Pharvaris during the third quarter valued at $106,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Pharvaris during the 4th quarter worth about $111,000.

Pharvaris Company Profile

(Get Free Report)

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.